Danielle Nina Margalit, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Head and Neck Neoplasms | 33 | 2024 | 2931 | 4.270 |
Why?
|
Oropharyngeal Neoplasms | 14 | 2024 | 493 | 4.150 |
Why?
|
Carcinoma, Squamous Cell | 19 | 2024 | 4058 | 2.460 |
Why?
|
Carcinoma, Merkel Cell | 5 | 2024 | 329 | 2.330 |
Why?
|
Papillomavirus Infections | 11 | 2024 | 1640 | 1.830 |
Why?
|
Papillomaviridae | 9 | 2024 | 1140 | 1.670 |
Why?
|
Radiotherapy, Intensity-Modulated | 8 | 2022 | 798 | 1.550 |
Why?
|
Radium | 3 | 2022 | 70 | 1.050 |
Why?
|
Neoplasm Recurrence, Local | 18 | 2024 | 9419 | 0.960 |
Why?
|
Skin Neoplasms | 7 | 2024 | 5863 | 0.920 |
Why?
|
Granuloma, Plasma Cell | 1 | 2018 | 80 | 0.570 |
Why?
|
Neoadjuvant Therapy | 4 | 2024 | 2907 | 0.560 |
Why?
|
Financial Management | 1 | 2018 | 161 | 0.540 |
Why?
|
Mouth Diseases | 1 | 2018 | 239 | 0.510 |
Why?
|
Neoplasm Staging | 10 | 2024 | 11244 | 0.480 |
Why?
|
Radiotherapy Dosage | 8 | 2023 | 2916 | 0.480 |
Why?
|
Tooth Diseases | 1 | 2015 | 73 | 0.470 |
Why?
|
Carcinoma, Adenoid Cystic | 3 | 2021 | 263 | 0.450 |
Why?
|
Radiation Oncology | 2 | 2017 | 572 | 0.420 |
Why?
|
SEER Program | 4 | 2020 | 1444 | 0.400 |
Why?
|
Superoxide Dismutase | 1 | 2015 | 596 | 0.400 |
Why?
|
Mouth Neoplasms | 3 | 2024 | 597 | 0.390 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2018 | 1628 | 0.350 |
Why?
|
beta Carotene | 1 | 2011 | 523 | 0.340 |
Why?
|
Neoplasms, Second Primary | 3 | 2023 | 1061 | 0.320 |
Why?
|
Leadership | 1 | 2018 | 1397 | 0.310 |
Why?
|
Osteoradionecrosis | 2 | 2020 | 51 | 0.310 |
Why?
|
Humans | 71 | 2024 | 768171 | 0.300 |
Why?
|
Receptors, Progesterone | 1 | 2012 | 1160 | 0.290 |
Why?
|
Lymph Nodes | 2 | 2018 | 3474 | 0.280 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 4 | 2023 | 1679 | 0.280 |
Why?
|
Mastectomy, Segmental | 1 | 2012 | 974 | 0.280 |
Why?
|
Aged, 80 and over | 17 | 2024 | 59626 | 0.240 |
Why?
|
Aged | 28 | 2024 | 171502 | 0.240 |
Why?
|
Prostatic Neoplasms | 4 | 2020 | 11101 | 0.230 |
Why?
|
Radiotherapy | 1 | 2011 | 1502 | 0.230 |
Why?
|
Receptors, Estrogen | 1 | 2012 | 2253 | 0.230 |
Why?
|
Middle Aged | 29 | 2024 | 223487 | 0.230 |
Why?
|
Mastectomy | 1 | 2012 | 1862 | 0.220 |
Why?
|
Antioxidants | 1 | 2011 | 1676 | 0.220 |
Why?
|
Quality of Life | 2 | 2022 | 13490 | 0.220 |
Why?
|
Receptor, erbB-2 | 2 | 2020 | 2603 | 0.210 |
Why?
|
Medical Errors | 1 | 2011 | 1260 | 0.210 |
Why?
|
Retrospective Studies | 18 | 2024 | 81760 | 0.200 |
Why?
|
Clinical Trials as Topic | 1 | 2018 | 8052 | 0.200 |
Why?
|
Combined Modality Therapy | 5 | 2023 | 8542 | 0.200 |
Why?
|
Rectal Neoplasms | 1 | 2011 | 1183 | 0.190 |
Why?
|
Male | 33 | 2024 | 364731 | 0.190 |
Why?
|
Tonsillar Neoplasms | 1 | 2021 | 50 | 0.180 |
Why?
|
Antineoplastic Agents | 3 | 2020 | 13677 | 0.180 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2020 | 1791 | 0.180 |
Why?
|
Female | 31 | 2024 | 397187 | 0.180 |
Why?
|
Societies, Medical | 2 | 2023 | 3968 | 0.170 |
Why?
|
Radiation Dosage | 3 | 2023 | 1967 | 0.170 |
Why?
|
Kaplan-Meier Estimate | 3 | 2020 | 6525 | 0.170 |
Why?
|
Cytoskeletal Proteins | 1 | 2004 | 1327 | 0.160 |
Why?
|
Lung Neoplasms | 1 | 2023 | 13586 | 0.160 |
Why?
|
Dental Porcelain | 1 | 2018 | 68 | 0.150 |
Why?
|
Osteonecrosis | 1 | 2020 | 230 | 0.150 |
Why?
|
Dental Materials | 1 | 2018 | 113 | 0.150 |
Why?
|
Sarcopenia | 1 | 2023 | 378 | 0.150 |
Why?
|
Hypokalemia | 1 | 2019 | 152 | 0.150 |
Why?
|
Palate, Hard | 1 | 2018 | 59 | 0.150 |
Why?
|
Mucositis | 1 | 2019 | 108 | 0.150 |
Why?
|
Disease-Free Survival | 5 | 2021 | 6847 | 0.150 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2019 | 102 | 0.150 |
Why?
|
Radiotherapy, Conformal | 2 | 2011 | 549 | 0.150 |
Why?
|
Oropharynx | 1 | 2018 | 139 | 0.140 |
Why?
|
Neck | 1 | 2022 | 736 | 0.140 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2024 | 3556 | 0.140 |
Why?
|
Peer Review, Health Care | 1 | 2017 | 73 | 0.140 |
Why?
|
Carotid Stenosis | 1 | 2024 | 859 | 0.140 |
Why?
|
Maximum Tolerated Dose | 1 | 2019 | 899 | 0.130 |
Why?
|
Salivary Gland Neoplasms | 1 | 2020 | 306 | 0.130 |
Why?
|
Treatment Outcome | 11 | 2021 | 65379 | 0.130 |
Why?
|
Hyperbaric Oxygenation | 1 | 2017 | 166 | 0.130 |
Why?
|
Lymphatic Metastasis | 2 | 2015 | 2914 | 0.130 |
Why?
|
Dental Care | 1 | 2019 | 286 | 0.130 |
Why?
|
Asymptomatic Diseases | 1 | 2018 | 590 | 0.120 |
Why?
|
Genetic Association Studies | 2 | 2015 | 2744 | 0.120 |
Why?
|
Prognosis | 6 | 2024 | 30009 | 0.110 |
Why?
|
Postoperative Period | 1 | 2019 | 1826 | 0.110 |
Why?
|
Proportional Hazards Models | 4 | 2019 | 12543 | 0.110 |
Why?
|
Protons | 1 | 2019 | 1113 | 0.110 |
Why?
|
Enzyme Inhibitors | 1 | 2004 | 3728 | 0.110 |
Why?
|
Immunocompromised Host | 1 | 2019 | 863 | 0.110 |
Why?
|
Incidence | 3 | 2024 | 21538 | 0.110 |
Why?
|
Adenocarcinoma | 1 | 2011 | 6395 | 0.110 |
Why?
|
Survival Analysis | 4 | 2020 | 10099 | 0.110 |
Why?
|
Fatal Outcome | 1 | 2018 | 1836 | 0.110 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2018 | 737 | 0.110 |
Why?
|
Cancer Care Facilities | 2 | 2019 | 427 | 0.110 |
Why?
|
Prospective Studies | 7 | 2020 | 54924 | 0.110 |
Why?
|
Bone Density Conservation Agents | 1 | 2020 | 797 | 0.100 |
Why?
|
Leg | 1 | 2018 | 1088 | 0.100 |
Why?
|
Diarrhea | 1 | 2019 | 1320 | 0.100 |
Why?
|
Adult | 16 | 2024 | 223646 | 0.100 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 11878 | 0.100 |
Why?
|
Saliva | 1 | 2017 | 853 | 0.100 |
Why?
|
Survivors | 1 | 2022 | 2381 | 0.100 |
Why?
|
Carcinoma | 1 | 2023 | 2332 | 0.100 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 905 | 0.090 |
Why?
|
Radiation Injuries | 1 | 2019 | 1198 | 0.090 |
Why?
|
United States | 5 | 2023 | 73039 | 0.090 |
Why?
|
Endoribonucleases | 1 | 2013 | 231 | 0.090 |
Why?
|
Drug Administration Schedule | 1 | 2019 | 4861 | 0.090 |
Why?
|
Bacterial Proteins | 1 | 2004 | 3840 | 0.090 |
Why?
|
Palatine Tonsil | 2 | 2021 | 193 | 0.090 |
Why?
|
Consensus | 1 | 2020 | 3211 | 0.090 |
Why?
|
Breast Neoplasms | 2 | 2020 | 21207 | 0.090 |
Why?
|
Axilla | 1 | 2012 | 623 | 0.080 |
Why?
|
Young Adult | 6 | 2020 | 60066 | 0.080 |
Why?
|
Immunoenzyme Techniques | 1 | 2012 | 1703 | 0.080 |
Why?
|
Radiation Tolerance | 1 | 2011 | 476 | 0.080 |
Why?
|
Recurrence | 2 | 2020 | 8509 | 0.080 |
Why?
|
Neoplasms | 1 | 2018 | 22371 | 0.080 |
Why?
|
Killer Cells, Natural | 1 | 2018 | 2211 | 0.080 |
Why?
|
Quality Control | 1 | 2011 | 836 | 0.080 |
Why?
|
Documentation | 1 | 2015 | 917 | 0.080 |
Why?
|
Medical Oncology | 1 | 2020 | 2346 | 0.070 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 1767 | 0.070 |
Why?
|
Pyrazoles | 1 | 2018 | 2028 | 0.070 |
Why?
|
Multiple Sclerosis | 1 | 2022 | 3250 | 0.070 |
Why?
|
Organs at Risk | 2 | 2022 | 367 | 0.070 |
Why?
|
Prostatectomy | 2 | 2013 | 1786 | 0.070 |
Why?
|
Silent Information Regulator Proteins, Saccharomyces cerevisiae | 1 | 2007 | 62 | 0.070 |
Why?
|
Practice Guidelines as Topic | 2 | 2024 | 7454 | 0.070 |
Why?
|
Hospitalization | 2 | 2020 | 10840 | 0.070 |
Why?
|
Lymph Node Excision | 1 | 2012 | 1271 | 0.070 |
Why?
|
Germ-Line Mutation | 1 | 2015 | 1885 | 0.070 |
Why?
|
Pyridines | 1 | 2018 | 2894 | 0.060 |
Why?
|
Confidence Intervals | 1 | 2011 | 2923 | 0.060 |
Why?
|
Quality Assurance, Health Care | 2 | 2017 | 2176 | 0.060 |
Why?
|
Antibodies, Viral | 1 | 2017 | 3214 | 0.060 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2012 | 934 | 0.060 |
Why?
|
Patient Education as Topic | 1 | 2015 | 2337 | 0.060 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2018 | 4648 | 0.060 |
Why?
|
Early Detection of Cancer | 1 | 2019 | 3239 | 0.060 |
Why?
|
Neoplasm Invasiveness | 1 | 2012 | 3620 | 0.060 |
Why?
|
Genomics | 1 | 2020 | 5926 | 0.060 |
Why?
|
Sirtuins | 1 | 2007 | 322 | 0.060 |
Why?
|
Biopolymers | 1 | 2004 | 183 | 0.050 |
Why?
|
Cisplatin | 2 | 2020 | 1660 | 0.050 |
Why?
|
Neoplasm Metastasis | 3 | 2020 | 4913 | 0.050 |
Why?
|
Palliative Care | 1 | 2018 | 3643 | 0.050 |
Why?
|
Survival Rate | 2 | 2017 | 12840 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3115 | 0.050 |
Why?
|
Histone Deacetylases | 1 | 2007 | 717 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3238 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2018 | 8648 | 0.050 |
Why?
|
Prostate-Specific Antigen | 1 | 2011 | 2463 | 0.050 |
Why?
|
Registries | 1 | 2018 | 8375 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 1 | 2018 | 5704 | 0.050 |
Why?
|
Diagnostic Imaging | 1 | 2015 | 3533 | 0.050 |
Why?
|
Cohort Studies | 4 | 2020 | 41753 | 0.050 |
Why?
|
Parotid Gland | 1 | 2022 | 178 | 0.050 |
Why?
|
Logistic Models | 2 | 2017 | 13290 | 0.050 |
Why?
|
Cause of Death | 1 | 2011 | 3721 | 0.050 |
Why?
|
Retreatment | 1 | 2022 | 598 | 0.040 |
Why?
|
Pandemics | 1 | 2020 | 8747 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2015 | 13013 | 0.040 |
Why?
|
Risk Factors | 4 | 2024 | 74944 | 0.040 |
Why?
|
Community Medicine | 1 | 2019 | 23 | 0.040 |
Why?
|
Bone Neoplasms | 1 | 2011 | 2565 | 0.040 |
Why?
|
Dental Alloys | 1 | 2018 | 29 | 0.040 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2004 | 1339 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 2 | 2023 | 20762 | 0.040 |
Why?
|
Odds Ratio | 1 | 2011 | 9669 | 0.040 |
Why?
|
Structure-Activity Relationship | 1 | 2004 | 3056 | 0.040 |
Why?
|
Follow-Up Studies | 3 | 2019 | 39354 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2015 | 15453 | 0.040 |
Why?
|
Boston | 1 | 2011 | 9374 | 0.040 |
Why?
|
Tongue | 1 | 2021 | 406 | 0.040 |
Why?
|
Zirconium | 1 | 2018 | 110 | 0.040 |
Why?
|
Androgen Antagonists | 2 | 2020 | 1412 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2015 | 16044 | 0.040 |
Why?
|
Double-Blind Method | 1 | 2011 | 12466 | 0.040 |
Why?
|
Electronic Health Records | 1 | 2015 | 4887 | 0.040 |
Why?
|
Dentists | 1 | 2019 | 176 | 0.040 |
Why?
|
Dental Prosthesis Design | 1 | 2018 | 263 | 0.030 |
Why?
|
Jaw | 1 | 2017 | 95 | 0.030 |
Why?
|
Protein Conformation | 1 | 2004 | 3956 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2016 | 53 | 0.030 |
Why?
|
Saccharomyces cerevisiae | 1 | 2007 | 2682 | 0.030 |
Why?
|
Tumor Burden | 1 | 2021 | 1906 | 0.030 |
Why?
|
Mucous Membrane | 1 | 2019 | 659 | 0.030 |
Why?
|
Materials Testing | 1 | 2018 | 873 | 0.030 |
Why?
|
Smoking | 1 | 2012 | 9092 | 0.030 |
Why?
|
Polymerase Chain Reaction | 1 | 2024 | 6082 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2021 | 1273 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12077 | 0.030 |
Why?
|
Age Factors | 1 | 2011 | 18415 | 0.030 |
Why?
|
Cyclin D1 | 1 | 2016 | 453 | 0.030 |
Why?
|
Nutrition Surveys | 1 | 2021 | 1738 | 0.030 |
Why?
|
Oral Health | 1 | 2019 | 493 | 0.030 |
Why?
|
Mycobacterium tuberculosis | 1 | 2004 | 1930 | 0.030 |
Why?
|
Receptor, Notch1 | 1 | 2016 | 519 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 710 | 0.030 |
Why?
|
Escherichia coli | 1 | 2004 | 4213 | 0.020 |
Why?
|
Adaptation, Psychological | 1 | 2022 | 2663 | 0.020 |
Why?
|
Antibody Formation | 1 | 2016 | 1393 | 0.020 |
Why?
|
Immunity, Cellular | 1 | 2016 | 1561 | 0.020 |
Why?
|
Risk Assessment | 2 | 2024 | 24318 | 0.020 |
Why?
|
Immunologic Factors | 1 | 2019 | 1596 | 0.020 |
Why?
|
DNA | 1 | 2022 | 7213 | 0.020 |
Why?
|
Patient Compliance | 1 | 2019 | 2697 | 0.020 |
Why?
|
Chronic Disease | 1 | 2022 | 9384 | 0.020 |
Why?
|
Anxiety | 1 | 2022 | 4672 | 0.020 |
Why?
|
Organisms, Genetically Modified | 1 | 2007 | 63 | 0.020 |
Why?
|
Hematologic Neoplasms | 1 | 2019 | 1907 | 0.020 |
Why?
|
Sirtuin 2 | 1 | 2007 | 93 | 0.020 |
Why?
|
Adolescent | 1 | 2015 | 89169 | 0.020 |
Why?
|
Genetic Complementation Test | 1 | 2007 | 557 | 0.020 |
Why?
|
Anti-Bacterial Agents | 1 | 2004 | 7477 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2016 | 2956 | 0.020 |
Why?
|
Base Sequence | 1 | 2016 | 12422 | 0.010 |
Why?
|
Prostate | 1 | 2013 | 1765 | 0.010 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2013 | 1536 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2022 | 20225 | 0.010 |
Why?
|
Decision Making | 1 | 2018 | 3953 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2016 | 3604 | 0.010 |
Why?
|
Quality Improvement | 1 | 2019 | 3857 | 0.010 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2016 | 3670 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2012 | 6229 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2013 | 3229 | 0.010 |
Why?
|
Algorithms | 1 | 2023 | 14164 | 0.010 |
Why?
|
Stroke | 1 | 2024 | 9755 | 0.010 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2007 | 724 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 26379 | 0.010 |
Why?
|
Cytokines | 1 | 2016 | 7452 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2013 | 3858 | 0.010 |
Why?
|
Gene Silencing | 1 | 2007 | 1505 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2016 | 9540 | 0.010 |
Why?
|
Gene Deletion | 1 | 2007 | 2674 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2016 | 9617 | 0.010 |
Why?
|
Genotype | 1 | 2013 | 13045 | 0.010 |
Why?
|
Sex Factors | 1 | 2012 | 10632 | 0.010 |
Why?
|
Phosphoproteins | 1 | 2007 | 2451 | 0.010 |
Why?
|
Saccharomyces cerevisiae Proteins | 1 | 2007 | 1839 | 0.010 |
Why?
|
Alleles | 1 | 2007 | 6894 | 0.010 |
Why?
|
Cell Cycle Proteins | 1 | 2007 | 3445 | 0.010 |
Why?
|
Protein Binding | 1 | 2007 | 9343 | 0.010 |
Why?
|
Inflammation | 1 | 2013 | 10873 | 0.010 |
Why?
|
HIV Infections | 1 | 2019 | 17569 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 2007 | 5804 | 0.010 |
Why?
|